CHO Pharma Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
40
- Stock Symbol
-
6586
- Share Price
-
$2.73
- (As of Monday Closing)
CHO Pharma General Information
Description
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
Contact Information
Website
www.chopharma.comCorporate Office
- 18F, Building F, No. 3
- Park Street, Nangang
- Taipei, 115-03
- Taiwan
Corporate Office
- 18F, Building F, No. 3
- Park Street, Nangang
- Taipei, 115-03
- Taiwan
CHO Pharma Stock Performance
As of 16-Nov-2026, CHO Pharma’s stock price is $2.73. Its current market cap is $583M with 214M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.73 | $2.32 | $0.71 - $4.66 | $583M | 214M | 495K | -$0.04 |
CHO Pharma Financials Summary
As of 30-Jun-2026, CHO Pharma has a trailing 12-month revenue of $54.9K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 824,899 | 121,783 | 257,294 | 383,710 |
| Revenue | 55 | 46 | 112 | 0 |
| EBITDA | (8,955) | (9,590) | (6,959) | (9,438) |
| Net Income | (8,628) | (9,296) | (6,613) | (9,827) |
| Total Assets | 77,294 | 82,267 | 87,620 | 100,431 |
| Total Debt | 230 | 466 | 879 | 0 |
CHO Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CHO Pharma Patents
CHO Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024204980-A1 | Fucosidase mutants and the use thereof | Pending | 28-Jul-2023 | ||
| EP-4509598-A1 | Fucosidase mutants and the use thereof | Active | 28-Jul-2023 | ||
| EP-4509598-B1 | Fucosidase mutants and the use thereof | Active | 28-Jul-2023 | ||
| EP-4509598-C0 | Fucosidase mutants and the use thereof | Active | 28-Jul-2023 | ||
| ES-3073626-T3 | Fucosidase mutants and the use thereof | Active | 28-Jul-2023 | C12N9/2402 |
CHO Pharma Signals
CHO Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
CHO Pharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cho Pharma Usa | Woburn, MA | 2019 |
CHO Pharma FAQs
-
When was CHO Pharma founded?
CHO Pharma was founded in 2013.
-
Where is CHO Pharma headquartered?
CHO Pharma is headquartered in Taipei, Taiwan.
-
What is the size of CHO Pharma?
CHO Pharma has 40 total employees.
-
What industry is CHO Pharma in?
CHO Pharma’s primary industry is Drug Discovery.
-
Is CHO Pharma a private or public company?
CHO Pharma is a Public company.
-
What is CHO Pharma’s stock symbol?
The ticker symbol for CHO Pharma is 6586.
-
What is the current stock price of CHO Pharma?
As of 16-Nov-2026 the stock price of CHO Pharma is $2.73.
-
What is the current market cap of CHO Pharma?
The current market capitalization of CHO Pharma is $583M.
-
What is CHO Pharma’s current revenue?
The trailing twelve month revenue for CHO Pharma is $54.9K.
-
What is CHO Pharma’s annual earnings per share (EPS)?
CHO Pharma’s EPS for 12 months was -$0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process